Red Orbit (Free subscription) | 05/15/2008
Biopharmaceutical firm Geron has granted a license to Stemcell Technologies, under Geron intellectual property relating to primate pluripotent stem cells, including human embryonic stem cells.
The Street (Free subscription) | 05/15/2008
Geron takes back some of the previous day's big loss.
IPBiz (Free subscription) | 05/15/2008
On May 14, it was announced that the FDA placed a so-called clinical hold on their proposed test of the treatment for people with spinal injuries.
The San Francisco Business Times (Free subscription) | 05/14/2008
Geron Corp. said Wednesday that the Food and Drug Administration put a clinical hold on the company's proposed treatment for spinal cord injuries. (GERN)
Fiercebiotech (Free subscription) | 05/15/2008
Getting an embryonic stem cell therapy through clinical trials in the U.S. is looking like an increasingly tough challenge after Geron announced that the FDA is delaying a study of its experimental Read more...
bizjournals (Free subscription) | 05/14/2008
Biopharmaceutical company Geron Corp. said Wednesday a hold was placed by the Food and Drug Administration on GRNOPC1, the company's experimental cell therapy for spinal cord injury. (GERN)
EuroInvestor.co.uk (Free subscription) | 05/14/2008
STEMCELL Technologies, Inc. and Geron Corporation (Nasdaq:GERN) today announced that Geron has granted a license to STEMCELL Technologies ( “ STEMCELL Read more
Business Wire (Free subscription) | 05/14/2008
VANCOUVER & MENLO PARK, Calif.--(BUSINESS WIRE)--STEMCELL Technologies, Inc. and Geron Corporation (Nasdaq:GERN) today announced that Geron has granted a license to STEMCELL Technologies (
24/7 Wall St. (Free subscription) | 05/14/2008
Geron Corporation (NASDAQ: GERN) announced today that the company received a verbal notice from the FDA that Geron's Investigational New Drug (IND) submission... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Red Orbit (Free subscription) | 05/14/2008
Geron Corporation (Nasdaq:GERN) announced today that the company received verbal notice today from the FDA that the company's Investigational New Drug (IND) submission for GRNOPC1, a cell therapy for spinal cord injury, has been placed on clinical hold.
Antibody Technologies (Free subscription) | 05/15/2008
... stage development. Get on board with MDS Pharma Services. Quality. On Time. (TM) • FDA Places Geron Corporation ( GERN )'s GRNOPC1 IND on Clinical Hold More... • Valeant Pharmaceuticals International ( VRX ) Announces FDA Has Initiated Reconsideration of Generic Efudex(R) Approval More... • Lpath, Inc. 's iSONEP(TM) IND Application Gets Green Light From FDA More... • Orexo AB Has Submitted...
Business Wire (Free subscription) | 05/14/2008
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) announced today that the company received verbal notice today from the FDA that the company's
Red Orbit (Free subscription) | 05/12/2008
Geron Corporation (Nasdaq:GERN) today announced that David L. Greenwood., executive vice president and chief financial officer, will present an update of the company's product development programs at 2:00 p.m.
Business Wire (Free subscription) | 05/12/2008
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced that David L. Greenwood., executive vice president and chief financial officer, will present an update of
jillstanek.com (Free subscription) | 8 hours ago
by JivinJ Looks like Geron will have to put off its human embryonic stem cell clinical trial on spinal cord injuries at least another year. At least the company apparently applied for a clinical trial this year as opposed to all the previous years where it promised to apply but never did. AZ's Board of Nursing has decided that nurse practitioners with special training can commit first-trimester...
